Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,605.21
(
0.34%
)
US TECH 100
23,520.00
(
0.52%
)
Dow Jones
46,619.01
(
0.25%
)
Brent Oil
106.68
(
-2.29%
)
Bitcoin
69,720.71
(
1.03%
)
News Focus
News Focus
Post# of 257363
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122852
Boards Moderated 8
Alias Born 09/05/2002

DewDiligence

Member Level

Re: RockRat post# 213524

Monday, 09/25/2017 2:57:18 PM

Monday, September 25, 2017 2:57:18 PM

Post# of 257363
NLNK,AZN collaborate on phase-2 of Indoximod + Imfinzi in pancreatic cancer:

https://globenewswire.com/news-release/2017/09/25/1131980/0/en/NewLink-Genetics-Announces-Clinical-Collaboration-to-Evaluate-IO-Based-Combination-Therapies-in-Pancreatic-Cancer.html

This collaboration differs in two respects from most checkpoint-inhibitor-plus-second-agent clinical-trial efforts incorporating drugs from two companies: 1) The companies are sharing the costs 50/50; and 2) The trial is randomized—i.e. it’s testing chemo ± (Indoximod + Imfinzi).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today